Generalized Anxiety Disorder

Neurology·MeSH: Generalized Anxiety Disorder

Prevalence

6090.6 / 100K

Incidence

716.2 / 100K/yr

11 drugs in development·9 companies·4 clinical trials

Drug Pipeline by Phase

Approved(5)

Drug	Company
buspirone	OXFORD IMMUNOTEC GLOBAL PLC (OXFD)
Cymbalta®	ELI LILLY & Co (LLY)
duloxetine	Inventiva S.A. (IVA)
paroxetine	Mylan II B.V. (MYL)
paroxetine	OXFORD IMMUNOTEC GLOBAL PLC (OXFD)

Phase 3(2)

Drug	Company
cyb004	CYBIN INC. (HELP)
effexor sr	Viatris Inc (VTRS)

Phase 2(4)

Drug	Company
ABBV-932	AbbVie Inc. (ABBV)
antidepressant therapy	AbbVie Inc. (ABBV)
ITI-1284-ODT-SL	Intra-Cellular Therapies, Inc. (ITCI)
psx-001	Incannex Healthcare Inc. (IXHL)

BioSniper tracks 11 drugs in development for Generalized Anxiety Disorder across 9 companies.

There are 4 clinical trials targeting Generalized Anxiety Disorder tracked by BioSniper.

The estimated prevalence of Generalized Anxiety Disorder is approximately 6090.6 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.